REPLIGEN CORP Adjustments to Additional Paid in Capital, Other
REPLIGEN CORP (RGEN) reported Adjustments to Additional Paid in Capital, Other of $105.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q/A filed 2024-11-18.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2024-11-18
- REPLIGEN CORP adjustments to additional paid in capital, other for the quarter ending 2022-09-30 was $105.00K.
- REPLIGEN CORP adjustments to additional paid in capital, other for the quarter ending 2022-06-30 was -$82.00K.
- REPLIGEN CORP adjustments to additional paid in capital, other for the quarter ending 2022-03-31 was -$24.00K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month |
|---|---|---|---|
| 2022-09-30 | $105.00K 10-Q/A · filed 2024-11-18 | $23.00K derived: sum of 2 quarters · filed 2024-11-18 | -$1.00K derived: sum of 3 quarters · filed 2024-11-18 |
| 2022-06-30 | -$82.00K 10-Q/A · filed 2024-11-18 | -$105.00K 10-Q/A · filed 2024-11-18 | |
| 2022-03-31 | -$24.00K 10-Q/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |